Partnering
Two ways to use this plant.
Either bring a finished product and use the capacity, or bring a target profile and use the development. Most partners start with the first and move to the second once they have watched a few batches come off the line.
- Licences
- G/25/2431 · G/28/1774
- Dosage forms
- Tablets and capsules
- Scales
- Lab · pilot · commercial
- Markets
- ROW · ASEAN · domestic
Contract manufacturing
Capacity that flexes with the market, not against it.
The reason to manufacture through a third party is rarely price alone — it is that demand moves and an owned plant cannot. Contract manufacturing lets production scale up or down with the market, which is what makes it worth doing at all.
- Site
- GIDC Naroda, Ahmedabad, GujaratLicence numbers G/25/2431 and G/28/1774
- Dosage forms
- Solid oral — tablets and capsules
- Annual capacity
- 1 billion general tablets and 220 million capsulesPlus 320 million effervescent tablets
- Batch sizes
- 10 kg to 240 kg
- Analytical support
- Comprehensive, in-house, across the whole programme
- Documentation
- Dossier support for filings with the corresponding health and drug authorities
Areas of partnering interest
Where a conversation is most likely to go somewhere.
Beyond the general range, these are the four areas the plant is actively looking to partner in — because the equipment, the formulation experience and the existing registrations are all already pointed at them.
01
Central nervous system
Antidepressants, antiepileptics and neuropathic pain combinations, in tablets and capsules.
02
Cardiovascular
The largest developed range on the site: antihypertensives, statins, anticoagulants and antiplatelets, singly and in fixed-dose combination.
03
Metabolic disorders
Anti-diabetic single agents and combinations, including the prolonged-release metformin systems that most combinations are built on.
04
Modified release
Sustained, prolonged, delayed and enteric-coated presentations — the formulation work that separates a contract manufacturer from a packer.
How a programme runs
From an enquiry to a commercial batch.
Nothing unusual, but stated, so that a first conversation can be about the product rather than about the process.
01
Brief
A molecule or a target profile, a market to file in, a volume and a landed cost. Enough to say yes, no, or "not at that price".
02
Feasibility
Formulation and development assess the route, the excipient system and the release behaviour, and confirm what the plant can hold to.
03
Development and scale-up
Lab scale to pilot to commercial, with analytical method development and stability running alongside rather than afterwards.
04
Documentation
Dossier data for submission to the corresponding health and drug authorities, prepared for the market being filed in.
05
Commercial supply
Manufacture, in-process and finished-product testing, release, and packing in the blister format the market takes.
Enquiry
Four lines is a complete enquiry.
Molecule, market, volume, target price. Send those and the reply will be specific — including a straight no where the answer is no, which saves everybody a quarter.